Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK.
BACKGROUND: In early 2005 the UK Committee on Safety of Medicines (CSM) announced gradual withdrawal of the analgesic co-proxamol because of its adverse benefit/safety ratio, especially its use for intentional and accidental fatal poisoning. Prescriptions of co-proxamol were reduced in the 3-year wi...
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Journal article |
| Taal: | English |
| Gepubliceerd in: |
2011
|
| _version_ | 1826256942702526464 |
|---|---|
| author | Hawton, K Bergen, H Waters, K Murphy, E Cooper, J Kapur, N |
| author_facet | Hawton, K Bergen, H Waters, K Murphy, E Cooper, J Kapur, N |
| author_sort | Hawton, K |
| collection | OXFORD |
| description | BACKGROUND: In early 2005 the UK Committee on Safety of Medicines (CSM) announced gradual withdrawal of the analgesic co-proxamol because of its adverse benefit/safety ratio, especially its use for intentional and accidental fatal poisoning. Prescriptions of co-proxamol were reduced in the 3-year withdrawal phase (2005 to 2007) following the CSM announcement. AIMS: To assess the impact of the CSM announcement in January 2005 to withdraw co-proxamol on nonfatal self-poisoning with co-proxamol and other analgesics. METHODS: Interrupted time series analysis of general hospital presentations for nonfatal self-poisoning (five hospitals in three centers in England), comparing the 3-year withdrawal period 2005-2007 with 2000-2004. RESULTS: A marked reduction in the number of episodes of nonfatal self-poisoning episodes involving co-proxamol was found following the CSM announcement (an estimated 62% over the period 2005 to 2007 compared to 2000 to 2004). There was no evidence of an increase in nonfatal self-poisoning episodes involving other analgesics (co-codamol, codeine, co-dydramol, dihydrocodeine, and tramadol) in relation to the CSM announcement over the same period, nor a change in the number of all episodes of self-poisoning. LIMITATIONS: Data were from three centers only. CONCLUSIONS: The impact of the policy appears to have reduced nonfatal self-poisoning with co-proxamol without significant substitution with other analgesics. This finding is in keeping with that for suicide. |
| first_indexed | 2024-03-06T18:10:17Z |
| format | Journal article |
| id | oxford-uuid:02c62c52-1ce1-4daa-88cd-6adde79988b5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:10:17Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:02c62c52-1ce1-4daa-88cd-6adde79988b52022-03-26T08:42:37ZImpact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:02c62c52-1ce1-4daa-88cd-6adde79988b5EnglishSymplectic Elements at Oxford2011Hawton, KBergen, HWaters, KMurphy, ECooper, JKapur, NBACKGROUND: In early 2005 the UK Committee on Safety of Medicines (CSM) announced gradual withdrawal of the analgesic co-proxamol because of its adverse benefit/safety ratio, especially its use for intentional and accidental fatal poisoning. Prescriptions of co-proxamol were reduced in the 3-year withdrawal phase (2005 to 2007) following the CSM announcement. AIMS: To assess the impact of the CSM announcement in January 2005 to withdraw co-proxamol on nonfatal self-poisoning with co-proxamol and other analgesics. METHODS: Interrupted time series analysis of general hospital presentations for nonfatal self-poisoning (five hospitals in three centers in England), comparing the 3-year withdrawal period 2005-2007 with 2000-2004. RESULTS: A marked reduction in the number of episodes of nonfatal self-poisoning episodes involving co-proxamol was found following the CSM announcement (an estimated 62% over the period 2005 to 2007 compared to 2000 to 2004). There was no evidence of an increase in nonfatal self-poisoning episodes involving other analgesics (co-codamol, codeine, co-dydramol, dihydrocodeine, and tramadol) in relation to the CSM announcement over the same period, nor a change in the number of all episodes of self-poisoning. LIMITATIONS: Data were from three centers only. CONCLUSIONS: The impact of the policy appears to have reduced nonfatal self-poisoning with co-proxamol without significant substitution with other analgesics. This finding is in keeping with that for suicide. |
| spellingShingle | Hawton, K Bergen, H Waters, K Murphy, E Cooper, J Kapur, N Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title | Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title_full | Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title_fullStr | Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title_full_unstemmed | Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title_short | Impact of withdrawal of the analgesic Co-proxamol on nonfatal self-poisoning in the UK. |
| title_sort | impact of withdrawal of the analgesic co proxamol on nonfatal self poisoning in the uk |
| work_keys_str_mv | AT hawtonk impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk AT bergenh impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk AT watersk impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk AT murphye impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk AT cooperj impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk AT kapurn impactofwithdrawaloftheanalgesiccoproxamolonnonfatalselfpoisoningintheuk |